

**18th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy  
Houston, TX, USA  
September 15-18, 2016**

These abstracts are presented in alphabetical order according to the name of the first author.

**CLINICAL POSTERS**

- POSTER 26: Factors associated with conception and pregnancy in CML patients on active imatinib therapy  
*Sheikh Ali and Salman Bashir*
- POSTER 27: RT-qPCR and RT-digital PCR: a comparison of different platforms for the evaluation of residual disease in chronic myeloid leukemia  
*Mary Alikian*
- POSTER 28: Early molecular response (EMR) at 3 months is predictive of better event-free survival (EFS) in patients with newly diagnosed chronic phase chronic myeloid leukemia (CP-CML) treated with imatinib  
*Manuel Ayala, Jacqueline Dominguez, Guadalupe Rodriguez, Moises Xolotl, Xochitl Aquino, Claudia Avitia, Dafné Moreno-Lorenzana and Antonieta Chavez-Gonzalez*
- POSTER 29: Outcomes of chronic phase chronic myeloid leukemia (CP-CML) patients with BCR-ABL1 transcript levels after 3 months of nilotinib as second line therapy  
*Manuel Ayala, Jacqueline Dominguez, Moises Xolotl, Guadalupe Rodriguez, Xochitl Aquino, Claudia Avitia, Dafné Moreno-Lorenzana and Antonieta Chavez-Gonzalez*
- POSTER 30: BCR-ABL1 monitoring on the I.S. using an analytically and clinically validated multiplex assay directly aligned to the WHO primary standards  
*Justin Brown, Walairat Laosinchai-Wolf, Marie Fahey, John Hedges, Adam Ruskin, Bernard Andruss and Ion Beldorth*
- POSTER 31: Patient-reported outcomes from an open-label safety and efficacy study of bosutinib in philadelphia chromosome-positive chronic myeloid leukemia resistant or intolerant to prior therapy  
*Jorge E. Cortes, Carla Mamolo, Yun Su, Arlene Reisman, Mark Shapiro and Jeff H. Lipton*
- POSTER 32: Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy  
*Zi Chen, Wei Wang, L. Jeffrey Medeiros, Shimin Hu*

- POSTER 33: Evaluation of Xpert<sup>®</sup> BCR-ABL ULTRA demonstrates a high ASSAY sensitivity with a limit of detection reaching MR4.5 and below  
*Christophe Ferrand, Marina Deschamps, Alba Levitas, Christina Lockwood, Jacqueline Payton, Geoffrey Uy, Charles Schiffer, Gerald Feldman, Aaron Bossler, Julie Woolworth, Alice Mims, Krupa Shridhar, Vivian Xiao, Natalie Wu, Huilin Wei, Chris Lykke, Michael Bates, Wendy Wong and Gwo-Jen Day*
- POSTER 34: Patient decision making about treatment discontinuation  
*Kathryn Flynn, Charles Schiffer, James Thompson and Ehab Atallah*
- POSTER 35: Early timepoint predictors of molecular responses in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). A multicentric study in Argentina  
*Isabel Giere, María José Mela Osorio, Federico Klosowski, Mariana Debus, Federico Sackmann, Miguel A. Pavlovsky, Isolda Fernandez, Beatriz Moiraghi, Ana Varela, Mariel Perez, Julio Pose, Georgina Bendek, Romina Mariano, Nicolas Cazap, Andres Brodsky, Isabel Annetta, Luciana Barazutti, Hector Hendler, Silvina Palmer, Carolina Pavlovsky*
- POSTER 36: Role of additional chromosomal alterations in chronic myeloid leukemia with variant Philadelphia translocations in the era of tyrosine kinase inhibitor therapy  
*Zimu Gong, Zi Chen, Wei Wang, L Jeffrey Medeiro, Shimin Hu*
- POSTER 37: T315I – a mutation that poses an impediment to complete cure for patients with chronic myeloid leukemia  
*Bushra Kaleem, Sadaf Shahab, Munira Borhany, Uzma Zaidi, Muhammad Nadeem and Tahir Shamsi*
- POSTER 38: Comparison of the frequency and sensitivity of BCR-ABL1 kinase domain mutations in Asian and Caucasian patients with imatinib-resistant chronic phase chronic myeloid leukemia  
*Hawk Kim, Hyeoung-Joon Kim, Yeo-Kyeoung Kim, Jae-Yong Kwak, Ho-Yong Yhim, Sung-Hyun Kim, Young Rok Do, Sukjoong Oh, Sung-Eun Lee, Saengsuree Jootar, Jiuwei Cui, Dong-Wook Kim*
- POSTER 39: Development of pulmonary arterial hypertension and change of right ventricular systolic pressure in chronic myeloid leukemia patients who treated with dasatinib  
*Jee Hyun Kong, Sung-Eun Lee, Soo Young Choi, Soo-Hyun Kim, Eun-Jung Jang, Suk Joong Oh, Hae-Eok Jung, Joon Seong Park, Sung-Hyun Kim, Dae Young Zang, Young Rok Do, Jae-Yong Kwak and Dong-Wook Kim*
- POSTER 40: Outcomes of chronic phase chronic myeloid leukemia in the era of multiple tyrosine kinase inhibitors: a single institution experience  
*Jee Hyun Kong, Vamsi Kota, Elliott.F Winton, Leonard.T Heffner, Manila Gaddh, Brittany Hill, Martha Arellano, Fuad El Rassi, Audrey Kim, Anand Jillella, Imre Bodó, H. Jean Houry*

- POSTER 41: e13a2 BCR-ABL1 transcript is associated with inferior molecular responses and a higher frequency of lymphoid crisis in patients with chronic myeloid leukemia at chronic phase treated with front-line imatinib  
*Ming-Chung Kuo, Ming-Chung Wang, Tsai-Yun Chen, Youngsen Yang, Su-Peng Yeh, Chih-Cheng Chen, Yu-Chieh Su, Pei-Ching Hsiao, Ming-Yang Lee, Wen-Li Hwang, Ching-Yuan Kuo, Tung-Huei Lin and Lee-Yung Shih*
- POSTER 42: Results and utility of kinase domain mutational analysis in patients with CML  
*Kimberley Lee, Doug Smith, Brooks Briel, Christopher Gocke, Jonathan Webster*
- POSTER 43: Predictors for 12-month major molecular response in CP CML patients who failed 3-month early molecular response with imatinib therapy  
*Sung-Eun Lee, Soo Young Choi, Soo-Hyun Kim, Hye-Young Song, Joon Seong Park, Sung-Hyun Kim, Dae Young Zang, Suk Joong Oh, Young Rok Do, Jae-Yong Kwak, Dong-Wook Kim*
- POSTER 44: Peroxisome proliferator-activated receptor (PPAR) gamma agonist in combination with BCR/ABL TKI in patients of CMP CP with suboptimal molecular response  
*Hemant Malhotra, Bharti Malhotra*
- POSTER 45: Ponatinib Therapy for philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) patients: real-world clinical practice versus the PACE trial  
*Michael J. Mauro, Lisa J. McGarry, Mo Yang, Stephanie Lustgarten, Hui Huang*
- POSTER 46: The PACE clinical trial vs. the real-world: comparison of ponatinib prescribing and duration of therapy in chronic phase-chronic myeloid leukemia (CP-CML) patients  
*Michael J. Mauro, Lisa J. McGarry, Mo Yang, Stephanie Lustgarten and Hui Huang*
- POSTER 47: Preliminary findings from a chart review of lower dosing of ponatinib in chronic myeloid leukemia (CML) patients  
*Michael J. Mauro, Lisa J. McGarry, Ani Inguilizian, Ruth du Moulin, Hui Huang*
- POSTER 48: Ponatinib versus bosutinib in 3rd-line chronic-phase chronic myeloid leukemia: indirect comparison of efficacy using iterative proportional fitting  
*Lisa J. McGarry, Mo Yang, Silvia Chirola, Stephanie Lustgarten and David J. Dorer*
- POSTER 49: JAK2 V617F positive polycythemia vera after four years of stable chronic myelogenous leukemia in complete molecular remission under imatinib treatment. Case report  
*Emilia Niculescu-Mizil*
- POSTER 50: Rapid achievement of MR4.5 after switching from imatinib to nilotinib in patients with chronic myeloid leukemia in chronic phase (CML-CP): preliminary results from ENESTgoal  
*Ellen K. Ritchie, Rebecca B Klisovic, Michael W. Deininger, Harry P Erba, Jerald Radich, Michael Savona, Carole S Paley, Ilva Dautaj, Michael Mauro*

- POSTER 51: Evaluation of miR-505-5p and miR-18a-5p as biomarkers of imatinib response in chronic myeloid leukemia patients  
*Suganthi S. Ramachandran, Pamchui Muiwo, Hafiz M. Ahmad, Ravindra Mohan Pandey, Sameer Bakhshi, Lalit Kumar, Alok Bhattacharya, Yogendra Kumar Gupta*
- POSTER 52: Clinical application of artificial intelligence in patients with chronic myeloid leukemia in chronic phase  
*Koji Sasaki, Hagop Kantarjian, Elias Jabbour, Susan O'Brien, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, William Wierda, Naval Daver, Koichi Takahashi, Preetesh Jain, Mary Rios, Sherry Pierce, Guillermo Garcia-Manero, Jorge E. Cortes*
- POSTER 53: Patient perspectives on enrollment in an adjuvant immunotherapy trial  
*Holly Taylor, Anna Ferguson and Doug Smith*
- POSTER 54: K562/GM-CSF booster vaccinations in combination with TKIs are associated with deeper molecular responses compared to TKI alone  
*Jonathan Webster, Anna Ferguson, Christopher Gocke, Rick Jones, Hyam Levitsky, Doug Smith*
- POSTER 55: Utilization and results of kinase domain mutational analysis to assess acquired TKI resistance at Johns Hopkins Hospital  
*Jonathan Webster, Kimberley Lee, Brooks Briel, Christopher Gocke, Doug Smith*